Document is current
Any future updates will be listed below
-
Authors
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Insel, Philip S
Stomrud, Erik
Janelidze, Shorena
Zetterberg, Henrik
Brix, Britta
Eichenlaub, Udo
Dage, Jeffrey L
Chai, Xiyun
Blennow, Kaj
Mattsson, Niklas https://orcid.org/0000-0002-8885-7724
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
-
Funding
Funding for this research was provided by:
H2020 European Research Council
Vetenskapsrådet
Knut och Alice Wallenbergs Stiftelse
- License Information
-
More Information
Article History
Received: 16 July 2019
Revised: 9 October 2019
Accepted: 14 October 2019
First Online: 11 November 2019
Conflict of interest
: SP, PSI, SJ, ES, and NM report no disclosures. UE is a current employee of the Roche Group. BB is a current employee of EUROIMMUN. JLD and XC are current employees of Lilly. KB has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics; is a co‐founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures‐based platform company at the University of Gothenburg; and has received research support (for the institution) from Roche Diagnostics and Fujirebio Europe. HZ has served at scientific advisory boards for Roche Diagnostics, Eli Lilly, and Wave; has received travel support from Teva; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures‐based platform company at the University of Gothenburg. OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Lilly, Roche, and Fujirebio.
